Clinical Trial: A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide Versus Placebo in Children and Adolescents With Hypochondroplasia

U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07917143) titled 'A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide Versus Placebo in Children and Adolescents With Hypochondroplasia' on Oct. 30.

Brief Summary: This trial is being conducted to evaluate the efficacy, safety and tolerability of treatment with navepegritide subcutaneous (SC) injections once weekly in children and adolescents with hypochondroplasia aged 2 to 17 years.

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Hypochondroplasia

Intervention: DRUG: Navepegritide

Administered weekly as s.c. injection. Treatment duration of up to 104 weeks

DRUG: Placebo for Navepegritide

Administered weekly ...